BOULDER, Colorado, September 17, 2021 (GLOBE NEWSWIRE) – Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company that strives to transform the lives of patients by developing treatments for innovative and differentiated prescription for the treatment of dermatological, autoimmune and other debilitating diseases, today announced that it is planned to host a Key Opinion Leaders (KOL) webinar on DYRK1A (Dual Specificity Tyrosine -Phosphorylation-Regulated Kinase 1A), which is believed to play a key role in autoimmune and inflammatory diseases, on Friday, September 24, 2021 at 10:00 a.m. EDT.
The webinar will include a presentation of KOL Bernard Khor, MD, Ph.D., Benaroya Research Institute at Virginia Mason, who will discuss the latest findings on the new target DYRK1A, its role in autoimmune and inflammatory diseases, and the broad therapeutic potential of restoring the immune homeostasis by inhibiting DYRK1A. Dr Khor will be available to answer questions after the official presentation.
The Brickell leadership team will also provide a brief update on the company’s DYRK1A inhibitor experimental platform. This includes BBI-02, which is a potential first-class, phase 1-ready oral DYRK1A inhibitor with promising preclinical validation and broad potential to treat autoimmune diseases including atopic dermatitis, rheumatoid arthritis and other debilitating inflammatory conditions.
To register for the webinar, please click here.
The webinar will be accessible via a webcast posted on the Events and Presentation page of the Investors section of the Brickell website at https://ir.brickellbio.com/events-presentations. For those who cannot watch this event broadcast live, a replay will be available on the Brickell website after the event.
Dr Bernard Khor joined the Benaroya Research Institute as an associate member in 2017. Dr Khor’s laboratory is interested in identifying new pathways that regulate tolerance and inflammation, focusing on targets drugs that are disrupted in the course of human autoimmunity. The current focus is on identifying new pathways that regulate the differentiation and function of Tregs. His group has identified DYRK1A as a novel regulator of Th17 / Treg differentiation and is working to understand the mechanical details of this regulation, as well as the translational relevance for precision medicine, for example in people with Down syndrome. Dr Khor received his BS in Biology from the Massachusetts Institute of Technology and his MD and PhD. in Immunology, Washington University in St. Louis. He did his residency in clinical pathology at Massachusetts General Hospital and fellowship in transfusion medicine at Harvard Medical School. Subsequently, he pursued postdoctoral research with Dr Ramnik Xavier.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to transforming the lives of patients by developing innovative and differentiated prescription therapies for the treatment of dermatological, autoimmune and other debilitating conditions. Brickell’s pipeline combines a best-in-class advanced clinical stage program for hyperhidrosis with a new, cutting-edge platform and developmental candidates with broad potential in autoimmune and neuro-disorders. inflammatory. Brickell’s management team and board of directors bring extensive experience in product development and global commercialization, having held leadership positions in large global pharmaceutical and biotechnology companies that have developed and / or launched products. successful, many of which were first in their class and / or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvéderm®. Brickell’s strategy is to leverage this experience to license, acquire, develop and commercialize innovative and differentiated pharmaceuticals that Brickell believes can significantly benefit patients with debilitating chronic diseases who are underserved by therapies available. For more information, visit https://www.brickellbio.com.
Caution Regarding Forward-Looking Statements
Any statement made in this press release regarding future financial, business and / or research and clinical performance, conditions, plans, prospects, trends or strategies and other similar matters, including, without exception y limit, the timing, scope, design and / or results of current and future preclinical and clinical trials, intellectual property rights, including the validity, duration and enforceability thereof, timing and / or the expected results of regulatory approvals and the size and marketing prospects of any of Brickell’s product candidates, or seeking collaborations with its partners, including in Japan, Korea, the United States or the United States. other countries, are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Additionally, when used in this press release, the words ” can ”,“ could ”,“ would ”,“ should ”,“ could ”,“ could ”,“ anticipate ”,“ believe ”,“ estimate ”,“ expect ”,“ intend ”,“ plan ” “,” Predict “,” potential “,” anticipate “similar expressions and variations thereof, with respect to Brickell, Kaken, Voronoi or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to many assumptions, risks and uncertainties, which change over time, often rapidly and in unforeseen ways. Important factors that may cause actual results to differ materially from results discussed in forward-looking statements or historical experience include risks and uncertainties, including, without limitation, research results and data which fail to meet objectives or expectations, the ability to obtain adequate funding to advance product development, the ability to maintain and enforce intellectual property rights, potential delays for any reason in the development of products and clinical trial enrollment, regulatory changes, supply chain disruptions, unanticipated demands for cash resources, any disruption to operations caused by the current COVID- 19 pandemic, interruptions, disruptions or inability by Kaken or Voronoi to supply and market research material and / or the produced in Japan or Korea, as the case may be, or to obtain or maintain an adequate price or reimbursement, the result of Brickell’s current and planned preclinical and clinical trials, and other risks associated with developing and obtaining the regulatory approval and market product candidates.
Further information on the factors and risks that could cause actual results to differ from forward-looking statements is contained in the documents filed by Brickell with the United States Securities and Exchange Commission (SEC), available at the address https://www.sec.gov. (or on https://www.brickellbio.com). Forward-looking statements represent Brickell’s estimates as of the date hereof only, and Brickell specifically disclaims any obligation or obligation to update any forward-looking statements.
Contact for Brickell investors: